APA

Chanthavanich P., Anderson E., Kerdpanich P., Bulitta M., Kanesa-Thasan N. & Hohenboken M. (20200422). Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects. : The Pediatric infectious disease journal.

Chicago

Chanthavanich Pornthep, Anderson Edwin, Kerdpanich Phirangkul, Bulitta Michael, Kanesa-Thasan Niranjan and Hohenboken Matthew. 20200422. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects. : The Pediatric infectious disease journal.

Harvard

Chanthavanich P., Anderson E., Kerdpanich P., Bulitta M., Kanesa-Thasan N. and Hohenboken M. (20200422). Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects. : The Pediatric infectious disease journal.

MLA

Chanthavanich Pornthep, Anderson Edwin, Kerdpanich Phirangkul, Bulitta Michael, Kanesa-Thasan Niranjan and Hohenboken Matthew. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects. : The Pediatric infectious disease journal. 20200422.